Osiris Therapeutics, Inc.  

(Public, NASDAQ:OSIR)   Watch this stock  
Find more results for OSIR
6.54
+0.14 (2.19%)
After Hours: 6.54 0.00 (0.00%)
Feb 10, 4:25PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.49 - 6.99
52 week 5.87 - 23.67
Open 6.49
Vol / Avg. 106,976.00/254,221.00
Mkt cap 231.47M
P/E 132.76
Div/yield 0.20
EPS 0.05
Shares 34.45M
Beta 0.94
Inst. own 42%
Mar 3, 2016
Q4 2015 Osiris Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 1, 2015
Osiris Therapeutics Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2015
Osiris Therapeutics Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 16, 2015
Osiris Therapeutics Inc at Brean Capital Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -2.60% -0.41%
Operating margin 1.22% 2.87%
EBITD margin - 4.44%
Return on average assets -2.59% -0.26%
Return on average equity -3.13% -0.30%
Employees 211 -
CDP Score - -

Address

7015 Albert Einstein Drive
COLUMBIA, MD 21046
United States - Map
+1-443-5451800 (Phone)
+1-443-5451701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Osiris Therapeutics, Inc. is a medical products company. The Company is focused on developing and marketing products in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. The Company's offers products in orthopedics, sports medicine and wound care, including Cartiform, BIO4 and Grafix. Cartiform is a viable chondral allograft containing viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the intact architecture of healthy hyaline cartilage. BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autograft that minimizes the potential for harvest site co-morbidities. Grafix is a cryopreserved placental membrane that preserves the native properties and inherent functionality of the tissue.

Officers and directors

Peter Friedli Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Dwayne Montgomery Interim Chief Executive Officer, Chief Operating Officer
Age: 48
Bio & Compensation  - Reuters
Gregory I. Law Chief Financial Officer, Corporate Secretary and Treasurer
Age: 48
Bio & Compensation  - Reuters
Frank D. Czworka Jr. Vice President, General Manager of Wound Care
Age: 46
Bio & Compensation  - Reuters
Adrian P. Mollo General Counsel
Age: 40
Bio & Compensation  - Reuters
Alla N. Danilkovitch Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Jonathan Mark Hopper Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Hans-Georg Klingemann M.D., Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 61
Bio & Compensation  - Reuters